Habenular O
and O
striatal O
activity O
during O
performance O
feedback O
are O
differentially O
linked O
with O
state-like O
and O
trait-like O
aspects O
of O
tobacco O
use O
disorder O
We O
dissociate O
brain O
changes O
linked O
to O
nicotine O
withdrawal O
in O
the O
habenula O
from O
those O
linked O
to O
addiction O
severity O
in O
striatum O
. O

The O
habenula O
, O
an O
epithalamic O
nucleus O
involved O
in O
reward O
and O
aversive O
processing O
, O
may O
contribute O
to O
negative O
reinforcement O
mechanisms O
maintaining O
nicotine O
use O
. O

We O
used O
a O
performance O
feedback O
task O
that O
differentially O
activates O
the O
striatum O
and O
habenula O
and O
administered O
nicotine O
and O
varenicline O
( O
versus O
placebos O
) O
to O
overnight-abstinent O
smokers O
and O
nonsmokers O
to O
delineate O
feedback-related O
functional O
brain O
alterations O
both O
as O
a O
function O
of O
smoking O
trait O
( O
smokers O
versus O
nonsmokers O
) O
and O
drug O
administration O
state O
( O
drug O
versus O
placebo O
) O
. O

Smokers O
showed O
less O
striatal O
responsivity O
to O
positive O
feedback O
, O
an O
alteration O
not O
mitigated O
by O
drug O
administration O
, O
but O
rather O
correlated O
with O
trait-level O
addiction O
severity O
. O

Conversely O
, O
nicotine O
administration O
reduced O
habenula O
activity O
following O
both O
positive O
and O
negative O
feedback O
among O
abstinent O
smokers O
, O
but O
not O
nonsmokers O
, O
and O
increased O
habenula O
activity O
among O
smokers O
correlated O
with O
elevated O
state-level O
tobacco O
cravings O
. O

These O
outcomes O
highlight O
a O
dissociation O
between O
neurobiological O
processes O
linked O
with O
the O
dependence O
severity O
trait O
and O
the O
nicotine O
withdrawal O
state O
. O

Interventions O
simultaneously O
targeting O
both O
aspects O
may O
improve O
currently O
poor O
cessation O
outcomes O
. O

MATERIALS O
AND O
METHODS O
Participants O
A O
total O
of O
24 O
nontreatment-seeking O
daily O
cigarette O
smokers O
( O
≥10 O
cigarettes/day O
for O
> O
2 O
years O
, O
12 O
females O
) O
and O
20 O
nonsmokers O
( O
no O
smoking O
within O
the O
last O
2 O
years O
and O
no O
lifetime O
history O
of O
daily O
smoking O
, O
10 O
females O
) O
completed O
the O
study O
. O

All O
44 O
participants O
were O
right-handed O
, O
were O
18 O
to O
55 O
years O
of O
age O
, O
and O
were O
recruited O
at O
the O
National O
Institute O
on O
Drug O
Abuse–Intramural O
Research O
Program O
( O
NIDA-IRP O
) O
in O
Baltimore O
, O
MD O
. O

Participants O
were O
healthy O
with O
no O
reported O
history O
of O
drug O
dependence O
( O
other O
than O
nicotine O
in O
smokers O
) O
, O
neurological O
or O
psychiatric O
disorders O
, O
cardiovascular O
or O
renal O
impairments O
, O
diabetes O
, O
or O
MRI O
contraindications O
. O

Cigarette O
smokers O
were O
36 O
± O
10 O
years O
old O
( O
mean O
± O
SD O
) O
, O
reported O
daily O
smoking O
for O
18 O
± O
11 O
years O
, O
smoked O
18 O
± O
8 O
cigarettes/day O
, O
and O
were O
moderately O
nicotine O
dependent O
( O
FTND O
scores O
: O
5 O
± O
2 O
; O
table O
S1 O
) O
. O

As O
nonsmokers O
were O
younger O
( O
30 O
± O
7 O
years O
old O
) O
than O
smokers O
, O
we O
considered O
the O
influence O
of O
age O
when O
comparing O
groups O
. O

The O
results O
and O
interpretations O
when O
including O
age O
as O
a O
covariate O
in O
between-group O
behavioral O
and O
neuroimaging O
assessments O
were O
the O
same O
as O
when O
age O
was O
not O
included O
. O

All O
participants O
’ O
data O
were O
used O
in O
behavioral O
assessments O
; O
however O
, O
for O
imaging O
assessments O
, O
fMRI O
data O
from O
two O
male O
smokers O
and O
one O
male O
nonsmoker O
were O
excluded O
because O
of O
excessive O
head O
motion O
during O
scanning O
( O
criteria O
described O
below O
) O
. O

We O
obtained O
written O
informed O
consent O
in O
accordance O
with O
the O
NIDA-IRP O
Institutional O
Review O
Board O
, O
and O
volunteers O
were O
compensated O
for O
participation O
. O

This O
study O
was O
registered O
at O
clinicaltrials.gov O
( O
NCT00830739 O
) O
. O

Experimental O
design O
and O
procedures O
We O
collected O
self-report O
questionnaire O
, O
behavioral O
task O
performance O
, O
and O
MRI O
data O
from O
participants O
in O
the O
context O
of O
a O
within-participant O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
, O
involving O
two O
drugs O
: O
transdermal O
nicotine O
( O
NicoDerm O
CQ O
, O
GlaxoSmithKline O
) O
and O
oral O
varenicline O
( O
Chantix O
, O
Pfizer O
) O
. O

The O
6- O
to O
8-week O
study O
duration O
involved O
a O
total O
of O
nine O
visits O
, O
each O
on O
different O
days O
( O
one O
orientation O
, O
two O
neurocognitive O
, O
and O
six O
neuroimaging O
visits O
; O
Fig O
. O

1A O
) O
. O

During O
the O
orientation O
visit O
, O
participants O
gave O
informed O
consent O
, O
completed O
baseline O
self-report O
measures O
, O
and O
received O
training O
on O
multiple O
neuroimaging O
tasks O
( O
one O
described O
herein O
) O
. O

Task O
instructions O
were O
initially O
explained O
at O
a O
bench O
computer O
, O
and O
then O
practice O
was O
completed O
in O
a O
mock O
MRI O
scanner O
. O

During O
the O
neurocognitive O
visits O
, O
participants O
completed O
self-report O
measures O
and O
behavioral O
testing O
( O
not O
described O
further O
) O
. O

At O
three O
time O
points O
during O
a O
varenicline O
administration O
regimen O
[ O
PILL O
factor O
: O
pre-pill O
( O
baseline O
) O
versus O
placebo O
versus O
varenicline O
] O
, O
participants O
completed O
MRI O
scanning O
on O
two O
occasions O
, O
once O
while O
wearing O
a O
nicotine O
patch O
and O
once O
while O
wearing O
a O
placebo O
patch O
( O
PATCH O
factor O
) O
. O

Following O
two O
initial O
pre-pill O
imaging O
sessions O
, O
each O
participant O
underwent O
~17 O
days O
of O
varenicline O
and O
placebo O
pill O
administration O
and O
completed O
nicotine O
and O
placebo O
patch O
visits O
toward O
the O
end O
of O
both O
pill O
periods O
. O

During O
each O
of O
the O
six O
neuroimaging O
days O
, O
participants O
completed O
two O
MRI O
sessions O
lasting O
~2 O
hours O
each O
( O
an O
a.m. O
and O
a O
p.m. O
session O
) O
. O

The O
a.m. O
session O
began O
~2 O
to O
2.5 O
hours O
after O
patch O
application O
. O

During O
this O
session O
, O
participants O
completed O
a O
Flanker O
task O
, O
a O
performance O
feedback O
task O
( O
described O
below O
) O
, O
and O
a O
response O
inhibition O
task O
. O

The O
performance O
feedback O
task O
was O
completed O
~45 O
min O
after O
scanner O
entry O
and O
2.5 O
to O
3.5 O
hours O
after O
patch O
application O
. O

Varenicline O
was O
administered O
according O
to O
standard O
guidelines O
beginning O
with O
a O
once-daily O
dose O
of O
0.5 O
mg O
on O
days O
1 O
to O
3 O
, O
0.5 O
mg O
twice O
daily O
on O
days O
4 O
to O
7 O
, O
and O
increased O
to O
1 O
mg O
twice O
daily O
on O
days O
8 O
to O
17 O
. O

( O
www.pfizer.com/products/product-detail/chantix O
) O
. O

Active O
varenicline O
and O
placebo O
pills O
were O
packaged O
to O
be O
identical O
in O
appearance O
. O

Scanning O
sessions O
occurred O
at O
the O
end O
of O
each O
regimen O
( O
varenicline O
, O
17.0 O
± O
4.2 O
days O
; O
placebo O
pill O
, O
16.5 O
± O
3.4 O
days O
) O
. O

Pill O
administration O
periods O
were O
not O
separated O
by O
a O
washout O
interval O
. O

For O
participants O
with O
a O
placebo O
regimen O
that O
followed O
the O
varenicline O
regimen O
, O
carryover O
effects O
were O
assumed O
negligible O
given O
the O
~24-hour O
elimination O
half-life O
of O
varenicline O
and O
the O
fact O
that O
placebo O
pill O
scanning O
sessions O
and O
active O
varenicline O
pill O
scanning O
sessions O
were O
separated O
by O
more O
than O
2 O
weeks O
. O

Adherence O
to O
the O
pill O
regimen O
was O
confirmed O
by O
pill O
count O
and O
participant O
self-report O
the O
morning O
of O
each O
MRI O
visit O
; O
data O
on O
medication O
adherence O
have O
been O
reported O
elsewhere O
. O

Pill O
regimen O
side O
effects O
and O
adherence O
were O
monitored O
by O
regular O
telephone O
assessments O
and O
at O
in-person O
visits O
. O

For O
each O
of O
the O
pill O
conditions O
, O
nicotine O
or O
placebo O
patches O
were O
applied O
to O
the O
upper O
back O
at O
the O
start O
of O
fMRI O
visits O
( O
separated O
by O
2.9 O
± O
1.7 O
days O
) O
. O

The O
patch O
was O
worn O
for O
the O
duration O
of O
each O
9-hour O
neuroimaging O
visit O
. O

Pharmacokinetic O
data O
indicate O
that O
plasma O
nicotine O
concentrations O
reach O
a O
peak O
within O
2 O
to O
4 O
hours O
after O
patch O
application O
, O
remain O
relatively O
stable O
for O
the O
next O
4 O
to O
6 O
hours O
, O
and O
then O
gradually O
decrease O
beginning O
~8 O
to O
10 O
hours O
after O
application O
. O

Hence O
, O
data O
collection O
occurred O
within O
a O
2- O
to O
9-hour O
postpatch O
window O
associated O
with O
steady O
plasma O
nicotine O
levels O
. O

All O
nonsmokers O
were O
administered O
7-mg O
nicotine O
patches O
. O

For O
smokers O
, O
a O
multiple O
dosing O
strategy O
was O
used O
to O
match O
daily O
nicotine O
intake O
: O
21 O
mg O
( O
10 O
to O
15 O
cigarettes/day O
; O
n O
= O
11 O
) O
, O
28 O
mg O
( O
16 O
to O
20 O
cigarettes/day O
; O
n O
= O
9 O
) O
, O
35 O
mg O
( O
21 O
to O
25 O
cigarettes/day O
; O
n O
= O
1 O
) O
, O
and O
42 O
mg O
( O
> O
25 O
cigarettes/day O
; O
n O
= O
3 O
) O
. O

Overnight O
abstinence O
was O
required O
on O
neuroimaging O
days O
. O

Smokers O
were O
instructed O
to O
have O
their O
last O
cigarette O
12 O
hours O
before O
their O
scheduled O
arrival O
. O

All O
participants O
were O
instructed O
to O
abstain O
from O
alcohol O
for O
24 O
hours O
and O
to O
moderate O
caffeine O
intake O
for O
12 O
hours O
. O

Upon O
arrival O
, O
all O
participants O
were O
tested O
for O
recent O
drug O
and O
alcohol O
use O
and O
for O
expired O
carbon O
monoxide O
( O
CO O
) O
levels O
. O

A O
CO O
guideline O
of O
less O
than O
15 O
parts O
per O
million O
( O
ppm O
) O
was O
used O
to O
verify O
smoking O
abstinence O
. O

Indicative O
of O
compliance O
, O
smokers O
’ O
CO O
levels O
were O
lower O
at O
neuroimaging O
visits O
( O
7.1 O
± O
2.6 O
ppm O
) O
in O
comparison O
to O
the O
orientation O
and O
neurocognitive O
visits O
that O
did O
not O
require O
abstinence O
[ O
18.9 O
± O
8.9 O
ppm O
; O
t O
( O
23 O
) O
= O
−8.2 O
, O
P O
< O
0.001 O
] O
. O

Nonsmokers O
’ O
CO O
levels O
did O
not O
differ O
between O
these O
visits O
( O
abstinence O
required O
, O
1.9 O
± O
0.3 O
ppm O
; O
not O
required O
, O
1.8 O
± O
0.4 O
ppm O
; O
P O
= O
0.2 O
) O
. O

Self-report O
measures O
We O
assessed O
clinically O
relevant O
constructs O
( O
addiction O
severity O
, O
tobacco O
craving O
, O
affect O
, O
and O
anhedonia O
) O
using O
previously O
validated O
and O
commonly O
used O
self-report O
instruments O
. O

In O
the O
context O
of O
cigarette O
smoking O
, O
addiction O
severity O
is O
typically O
quantified O
with O
the O
six-item O
FTND O
. O

FTND O
scores O
are O
highly O
heritable O
and O
routinely O
used O
as O
a O
primary O
phenotype O
in O
studies O
linking O
smoking O
behaviors O
with O
nAChR O
and O
other O
genetic O
variants O
. O

Hence O
, O
we O
conceptualized O
FTND O
scores O
( O
range O
, O
1 O
to O
10 O
) O
collected O
during O
the O
orientation O
visit O
as O
a O
trait-level O
measure O
of O
nicotine O
addiction O
severity O
. O

Additionally O
, O
smoker O
’ O
s O
tobacco O
cravings O
were O
assessed O
each O
neuroimaging O
visit O
with O
the O
12-item O
, O
short O
form O
of O
the O
TCQ O
. O

TCQ O
items O
were O
rated O
on O
a O
seven-point O
scale O
( O
strongly O
disagree O
to O
strongly O
agree O
) O
and O
yielded O
a O
total O
score O
( O
range O
, O
12 O
to O
84 O
) O
and O
four O
subscale O
scores O
( O
emotionality O
, O
expectancy O
, O
compulsivity O
, O
and O
purposefulness O
) O
. O

We O
focused O
on O
the O
TCQ O
total O
score O
that O
we O
conceptualized O
as O
a O
state-level O
measure O
of O
nicotine O
withdrawal O
status O
. O

All O
participants O
also O
completed O
instruments O
to O
assess O
affect O
and O
anhedonia O
at O
each O
neuroimaging O
visit O
. O

Specifically O
, O
participants O
completed O
the O
PANAS O
, O
which O
is O
composed O
of O
two O
10-item O
scales O
assessing O
positive O
affect O
( O
active O
, O
alert O
, O
attentive O
, O
determined O
, O
enthusiastic O
, O
excited O
, O
inspired O
, O
interested O
, O
proud O
, O
and O
strong O
) O
and O
negative O
affect O
( O
afraid O
, O
ashamed O
, O
distressed O
, O
guilty O
, O
hostile O
, O
irritable O
, O
jittery O
, O
nervous O
, O
scared O
, O
and O
upset O
) O
. O

PANAS O
items O
were O
rated O
on O
a O
five-point O
scale O
( O
not O
at O
all/very O
little O
to O
extremely O
) O
yielding O
positive O
and O
negative O
affect O
scores O
with O
a O
possible O
range O
from O
10 O
to O
50 O
. O

Participants O
also O
completed O
the O
RSAS O
, O
which O
is O
a O
40-item O
true-false O
questionnaire O
that O
measures O
pleasure O
( O
or O
lack O
thereof O
) O
derived O
from O
interpersonal O
sources O
. O

RSAS O
items O
are O
dichotomously O
scored O
, O
and O
total O
scores O
range O
from O
0 O
to O
40 O
such O
that O
higher O
values O
indicate O
greater O
levels O
of O
anhedonia O
. O

Elevated O
social O
anhedonia O
is O
common O
among O
individuals O
diagnosed O
with O
depression O
and O
schizophrenia O
, O
two O
neuropsychiatric O
conditions O
linked O
with O
aberrant O
habenula O
function O
and O
in O
which O
smokers O
are O
overrepresented O
. O

The O
TCQ O
( O
smokers O
only O
) O
, O
PANAS O
, O
and O
RSAS O
were O
collected O
each O
neuroimaging O
visit O
~1.5 O
hours O
after O
completion O
of O
the O
performance O
feedback O
task O
. O

Performance O
feedback O
task O
At O
each O
neuroimaging O
visit O
, O
participants O
performed O
a O
positive O
and O
negative O
performance O
feedback O
task O
, O
called O
the O
motion O
prediction O
task O
, O
previously O
shown O
to O
differentially O
activate O
the O
habenula O
, O
ACC O
, O
insula O
, O
and O
ventral O
striatum O
. O

The O
participants O
’ O
objective O
was O
to O
predict O
which O
of O
two O
moving O
balls O
, O
starting O
from O
different O
locations O
and O
traveling O
at O
different O
speeds O
, O
would O
be O
the O
first O
to O
reach O
a O
finish O
line O
after O
viewing O
a O
brief O
clip O
of O
the O
balls O
’ O
motion O
( O
Fig O
. O

1B O
) O
. O

Each O
trial O
began O
with O
a O
variable O
fixation O
interval O
( O
3500 O
to O
4500 O
ms O
) O
, O
which O
was O
followed O
by O
the O
appearance O
of O
the O
finish O
line O
( O
500 O
ms O
) O
to O
signify O
an O
upcoming O
motion O
event O
. O

Participants O
then O
viewed O
a O
short O
sequence O
( O
1400 O
ms O
) O
of O
the O
two O
balls O
traveling O
at O
different O
speeds O
from O
different O
starting O
locations O
on O
the O
left O
side O
of O
the O
screen O
toward O
the O
finish O
line O
on O
the O
right O
side O
of O
the O
screen O
. O

Still O
far O
from O
the O
finish O
line O
, O
the O
balls O
disappeared O
, O
and O
the O
question O
“ O
Which O
ball O
? O
” O
was O
presented O
( O
1350 O
ms O
) O
. O

Participants O
indicated O
their O
prediction/decision O
via O
a O
right-handed O
button O
press O
with O
either O
the O
index O
( O
ball O
1 O
) O
or O
middle O
finger O
( O
ball O
2 O
) O
during O
this O
response O
window O
. O

After O
a O
fixed O
delay O
( O
750 O
ms O
) O
, O
performance O
feedback O
( O
emojis O
) O
about O
the O
correctness O
of O
the O
participants O
’ O
prediction O
was O
presented O
( O
1000 O
ms O
) O
. O

Performance O
feedback O
was O
delivered O
to O
participants O
in O
a O
two-factor O
, O
FEEDBACK O
[ O
informative O
( O
i O
) O
versus O
noninformative O
( O
n O
) O
] O
* O
RESPONSE O
[ O
correct O
( O
C O
) O
versus O
error O
( O
E O
) O
] O
, O
fashion O
. O

Under O
informative O
feedback O
, O
participants O
always O
received O
positive O
feedback O
( O
i.e. O
, O
a O
happy O
emoji O
) O
following O
a O
correct O
response O
( O
iC O
) O
and O
always O
received O
negative O
feedback O
( O
i.e. O
, O
a O
sad O
emoji O
) O
following O
an O
erroneous O
response O
( O
iE O
) O
. O

Under O
noninformative O
feedback O
, O
participants O
received O
no O
information O
on O
whether O
they O
gave O
a O
correct O
or O
erroneous O
response O
as O
the O
same O
feedback O
was O
presented O
on O
both O
nC O
and O
nE O
trials O
( O
i.e. O
, O
an O
ambiguous O
emoji O
) O
. O

Informative O
feedback O
was O
presented O
on O
73 O
% O
of O
trials O
and O
noninformative O
feedback O
on O
27 O
% O
. O

This O
feedback O
schedule O
allowed O
us O
to O
determine O
which O
task-related O
aspect O
more O
robustly O
influenced O
brain O
activity O
, O
namely O
, O
the O
type O
of O
feedback O
( O
positive O
versus O
negative O
) O
or O
the O
type O
of O
response O
( O
correct O
versus O
error O
) O
. O

Task-related O
BOLD O
signal O
change O
was O
anticipated O
to O
be O
robustly O
modulated O
on O
error O
versus O
correct O
trials O
when O
followed O
by O
informative O
feedback O
. O

If O
participants O
failed O
to O
respond O
during O
the O
designated O
response O
window O
, O
then O
they O
received O
a O
fifth O
type O
of O
feedback O
( O
i.e. O
, O
a O
confused O
emoji O
) O
for O
these O
no-response O
trials O
. O

Task O
difficulty O
, O
operationalized O
as O
the O
time O
difference O
between O
the O
two O
balls O
’ O
arrival O
at O
the O
finish O
line O
, O
was O
dynamically O
manipulated O
on O
the O
basis O
of O
each O
participant O
’ O
s O
behavior O
to O
maintain O
error O
rates O
at O
~35 O
% O
( O
i.e. O
, O
an O
error O
rate O
between O
0.3 O
and O
0.4 O
over O
a O
sliding O
window O
) O
. O

Specifically O
, O
over O
a O
10-trial O
sliding O
window O
, O
if O
error O
rates O
were O
below O
0.3 O
, O
then O
task O
difficulty O
was O
increased O
, O
and O
if O
the O
rate O
was O
above O
0.4 O
, O
then O
task O
difficulty O
was O
decreased O
. O

This O
task O
feature O
was O
intended O
to O
induce O
participant O
uncertainty O
about O
trial O
performance O
until O
feedback O
delivery O
( O
i.e. O
, O
to O
mitigate O
the O
self-detection O
of O
errors O
) O
. O

While O
the O
dynamic O
difficulty O
manipulation O
was O
intended O
to O
consistently O
maintain O
error O
rates O
across O
participants O
and O
across O
the O
six O
neuroimaging O
visits O
, O
one O
behavioral O
aspect O
not O
under O
the O
control O
of O
the O
task O
’ O
s O
adaptive O
algorithm O
was O
the O
number O
of O
no-response O
trials O
( O
errors O
of O
omission O
) O
, O
which O
reflect O
momentary O
lapses O
of O
attention O
. O

For O
each O
no-response O
trial O
encountered O
, O
the O
adaptive O
algorithm O
reduced O
the O
targeted O
number O
of O
correct O
trials O
by O
one O
. O

Hence O
, O
the O
percent O
values O
of O
no-response O
and O
correct O
trials O
were O
inversely O
related O
, O
demonstrated O
more O
variability O
across O
participants O
and O
sessions O
than O
that O
for O
error O
trials O
, O
and O
thus O
provided O
a O
convenient O
behavioral O
metric O
to O
assess O
group- O
and O
drug-related O
effects O
on O
these O
two O
dependent O
variables O
, O
which O
we O
interpreted O
as O
gross O
behavioral O
measures O
of O
attention O
. O

Given O
that O
the O
percent O
of O
no-response O
and O
correct O
trials O
were O
“ O
mirror O
images O
” O
of O
each O
other O
, O
only O
no-response O
trial O
results O
are O
presented O
. O

Task O
presentation O
and O
behavioral O
performance O
recording O
were O
controlled O
by O
E-prime O
software O
( O
v1.2 O
, O
Psychology O
Software O
Tools O
) O
. O

Participants O
completed O
a O
total O
of O
240 O
trials O
in O
four O
9-min O
runs O
with O
short O
rest O
periods O
between O
runs O
1 O
to O
2 O
and O
3 O
to O
4 O
and O
a O
longer O
break O
between O
runs O
2 O
and O
3 O
( O
during O
which O
a O
T1-weighted O
structural O
MRI O
was O
collected O
and O
participants O
were O
instructed O
to O
relax O
while O
staying O
as O
still O
as O
possible O
) O
. O

Behavioral O
measures O
: O
Statistical O
analysis O
The O
primary O
behavioral O
performance O
measures O
considered O
from O
the O
task O
were O
RTs O
and O
the O
percent O
of O
no-response O
trials O
. O

To O
replicate O
outcomes O
from O
the O
original O
task O
implementation O
[ O
7 O
] O
and O
to O
assess O
task O
engagement O
, O
we O
analyzed O
RT O
data O
in O
a O
FEEDBACK O
[ O
informative O
( O
i O
) O
versus O
noninformative O
( O
n O
) O
] O
* O
RESPONSE O
[ O
correct O
( O
C O
) O
versus O
error O
( O
E O
) O
] O
repeated-measures O
ANOVA O
using O
SPSS O
( O
v23 O
, O
Chicago O
, O
IL O
) O
. O

As O
this O
analysis O
focused O
on O
the O
overall O
task O
effect O
( O
as O
opposed O
to O
session-specific O
fluctuations O
) O
, O
each O
participant O
’ O
s O
RT O
data O
were O
first O
averaged O
across O
all O
six O
neuroimaging O
visits O
( O
i.e. O
, O
collapsed O
across O
session O
) O
separately O
for O
each O
trial O
type O
. O

Main O
and O
interaction O
effects O
were O
considered O
. O

To O
characterize O
group O
effects O
and O
drug O
effects O
on O
an O
objective O
measure O
of O
attention O
, O
we O
analyzed O
the O
percent O
of O
no-response O
trials O
in O
a O
mixed-effects O
ANOVA O
, O
including O
factors O
for O
GROUP O
( O
between O
participants O
: O
smokers O
versus O
nonsmokers O
) O
, O
PATCH O
( O
within O
participants O
: O
nicotine O
versus O
placebo O
) O
, O
and O
PILL O
( O
within O
participants O
: O
pre-pill O
, O
varenicline O
, O
versus O
placebo O
) O
. O

Main O
and O
interaction O
effects O
were O
considered O
, O
and O
significant O
interactions O
involving O
the O
GROUP O
factor O
and/or O
a O
PATCH O
main O
effect O
were O
followed O
by O
within-group O
, O
repeated-measures O
ANOVAs O
including O
PATCH O
and O
PILL O
as O
factors O
. O

Geisser-Greenhouse O
corrections O
for O
violations O
of O
sphericity O
were O
used O
when O
considering O
effects O
involving O
the O
PILL O
factor O
( O
three O
levels O
) O
. O

Pairwise O
follow-up O
t O
tests O
comparing O
nicotine O
versus O
placebo O
PATCH O
differences O
( O
in O
the O
absence O
of O
varenicline O
under O
placebo O
pill O
conditions O
) O
and O
assessing O
varenicline O
versus O
placebo O
PILL O
differences O
( O
in O
the O
absence O
of O
nicotine O
under O
placebo O
patch O
conditions O
) O
were O
Bonferroni-corrected O
. O

All O
participants O
( O
N O
= O
44 O
) O
sufficiently O
performed O
the O
task O
and O
contributed O
behavioral O
data O
to O
these O
analyses O
. O

MRI O
data O
acquisition O
and O
analysis O
MRI O
data O
were O
collected O
on O
a O
Siemens O
3T O
Magnetom O
Allegra O
scanner O
( O
Erlangen O
, O
Germany O
) O
. O

During O
task O
performance O
, O
33 O
slices O
( O
5 O
mm O
thick O
) O
were O
obtained O
in O
the O
sagittal O
plane O
using O
a O
T2 O
* O
-weighted O
, O
single-shot O
, O
gradient-echo O
, O
EPI O
sequence O
sensitive O
to O
BOLD O
effects O
[ O
272 O
volumes O
per O
run O
, O
repetition O
time O
= O
2000 O
ms O
( O
332-ms O
delay O
) O
, O
echo O
time O
= O
27 O
ms O
, O
flip O
angle O
= O
80° O
, O
field O
of O
view O
= O
220 O
mm O
in O
a O
64 O
× O
64 O
matrix O
] O
. O

As O
simultaneous O
electroencephalography O
( O
EEG O
) O
data O
were O
also O
acquired O
( O
not O
discussed O
further O
) O
, O
sagittal O
images O
were O
collected O
with O
a O
delay O
between O
volume O
acquisitions O
to O
aid O
scanner-artifact O
removal O
from O
EEG O
recordings O
. O

T1-weighted O
structural O
images O
were O
obtained O
using O
a O
magnetization-prepared O
rapid O
gradient-echo O
sequence O
( O
MPRAGE O
: O
repetition O
time O
= O
2500 O
ms O
; O
echo O
time O
= O
4.38 O
ms O
; O
flip O
angle O
= O
8° O
; O
voxel O
size O
= O
1 O
mm3 O
) O
. O

Neuroimaging O
data O
were O
preprocessed O
and O
analyzed O
using O
Analysis O
of O
Functional O
NeuroImages O
( O
AFNI O
) O
( O
version O
16.3.18 O
; O
http O
: O
//afni.nimh.nih.gov/afni/ O
) O
. O

Functional O
images O
were O
slice O
time– O
and O
motion-corrected O
, O
registered O
to O
the O
anatomical O
volume O
, O
normalized O
into O
Talairach O
space O
( O
3-mm O
isotropic O
voxels O
, O
27 O
μl O
) O
, O
and O
spatially O
blurred O
to O
7-mm O
FWHM O
( O
AFNI O
’ O
s O
3dBlurToFWHM O
) O
. O

Following O
motion O
correction O
, O
functional O
volumes/frames O
with O
> O
0.35-mm O
Euclidean O
norm O
mean O
displacement O
were O
censored O
along O
with O
the O
immediately O
adjacent O
volumes O
. O

Those O
volumes O
with O
fewer O
than O
three O
contiguous O
uncensored O
neighbors O
were O
also O
flagged O
for O
censoring O
. O

Individual O
scanning O
sessions O
were O
excluded O
from O
imaging O
analyses O
if O
more O
than O
25 O
% O
of O
the O
functional O
volumes O
were O
motion-censored O
. O

This O
resulted O
in O
the O
exclusion O
of O
three O
male O
participants O
( O
two O
smokers O
and O
one O
nonsmoker O
) O
from O
further O
analyses O
given O
that O
a O
majority O
of O
their O
six O
neuroimaging O
sessions O
were O
flagged O
as O
high O
motion O
. O

Six O
additional O
participants O
had O
between O
one O
and O
three O
scanning O
sessions O
discarded O
from O
further O
analysis O
because O
of O
motion O
. O

Hence O
, O
41 O
participants O
( O
22 O
smokers O
and O
19 O
nonsmokers O
) O
contributed O
neuroimaging O
data O
to O
these O
analyses O
. O

Functional O
time O
series O
were O
normalized O
to O
percent O
signal O
change O
and O
submitted O
to O
voxel-wise O
multiple O
regression O
. O

In O
the O
first-level O
general O
linear O
model O
( O
GLM O
) O
, O
we O
included O
five O
separate O
task-related O
regressors O
as O
impulse O
functions O
time-locked O
to O
the O
onset O
of O
feedback O
presentation O
( O
iC O
, O
iE O
, O
nC O
, O
nE O
, O
and O
no O
response O
trials O
) O
. O

These O
regressors O
were O
convolved O
with O
a O
model O
hemodynamic O
response O
( O
gamma O
) O
function O
and O
its O
temporal O
derivatives O
. O

Regressors O
of O
no O
interest O
also O
included O
in O
the O
GLM O
were O
the O
six O
motion-correction O
parameters O
as O
well O
as O
fourth-order O
polynomial O
regressors O
to O
capture O
residual O
head O
motion O
and O
baseline O
trends O
in O
the O
BOLD O
signal O
, O
respectively O
. O

As O
the O
time O
series O
were O
scaled O
by O
the O
voxel-wise O
mean O
, O
resulting O
regression O
( O
β O
) O
coefficients O
, O
calculated O
per O
regressor O
, O
participant O
, O
and O
session O
, O
were O
interpreted O
as O
an O
approximation O
of O
percent O
BOLD O
signal O
change O
( O
% O
BOLD O
Δ O
) O
from O
the O
implicit O
baseline O
. O

Task O
effects O
To O
replicate O
outcomes O
from O
the O
original O
task O
implementation O
and O
to O
identify O
regions O
showing O
differential O
activity O
following O
performance O
feedback O
, O
we O
calculated O
contrast O
images O
between O
negative O
and O
positive O
feedback O
( O
iE O
− O
iC O
βs O
) O
. O

Individual O
participant O
’ O
s O
contrast O
images O
were O
first O
averaged O
across O
all O
sessions O
and O
then O
submitted O
to O
a O
group-level O
, O
whole-brain O
, O
one-sample O
t O
test O
( O
two O
tailed O
, O
3dTtest++ O
) O
. O

The O
resulting O
statistical O
maps O
were O
thresholded O
correcting O
for O
family-wise O
error O
at O
Pcorrected O
< O
0.001 O
[ O
Pvoxel-wise O
< O
0.0001 O
, O
cluster O
extent O
: O
15 O
voxels O
, O
51,704 O
voxels O
in O
the O
whole-brain O
mask O
, O
3dClustSim O
with O
the O
spatial O
autocorrelation O
function O
correction O
] O
. O

For O
graphical O
examination O
and O
follow-up O
analyses O
, O
we O
extracted O
the O
mean O
β O
coefficients O
associated O
with O
specific O
task O
events O
( O
iE O
, O
iC O
, O
nE O
, O
and O
nC O
) O
and O
the O
[ O
iE O
− O
iC O
] O
contrast O
values O
from O
the O
identified O
task-related O
clusters/ROIs O
by O
averaging O
across O
all O
voxels O
within O
each O
separate O
ROI O
. O

We O
performed O
exploratory O
bivariate O
Pearson O
’ O
s O
correlations O
between O
the O
contrast O
values O
( O
iE O
− O
iC O
βs O
) O
from O
pairs O
of O
identified O
ROIs O
to O
examine O
the O
relationship O
between O
the O
feedback-related O
responsivity O
of O
the O
habenula O
, O
insula O
, O
and O
ventral O
striatum O
. O

These O
exploratory O
correlation O
analyses O
were O
not O
Bonferronni-corrected O
for O
multiple O
comparisons O
. O

Group O
effects O
To O
characterize O
functional O
alterations O
linked O
with O
a O
chronic O
smoking O
history O
, O
we O
compared O
session-averaged O
( O
iE O
− O
iC O
) O
contrast O
images O
between O
smokers O
and O
nonsmokers O
in O
a O
two-tailed O
independent-samples O
t O
test O
( O
3dTtest++ O
) O
. O

Given O
our O
a O
priori O
focus O
on O
brain O
regions O
previously O
linked O
with O
addiction O
, O
nicotine O
withdrawal O
, O
and O
feedback O
processing O
in O
the O
MCL O
circuitry O
, O
we O
applied O
a O
family-wise O
error O
correction O
( O
Pcorrected O
< O
0.05 O
) O
within O
a O
composite O
mask O
of O
interest O
consisting O
of O
the O
bilateral O
nucleus O
accumbens O
, O
caudate O
, O
putamen O
, O
pallidum O
, O
anterior O
insula O
, O
anterior O
cingulate O
, O
middle O
anterior O
cingulate O
, O
subcallosal O
cingulate O
, O
and O
habenula O
regions O
( O
fig O
. O

S3 O
) O
. O

All O
anatomical O
masks O
came O
from O
the O
Desai O
maximum O
probability O
map O
, O
with O
the O
exception O
of O
the O
habenula O
mask O
that O
was O
defined O
by O
placing O
3-mm O
radius O
spheres O
around O
left O
and O
right O
hemisphere O
coordinates O
previously O
reported O
for O
the O
motion O
prediction O
task O
. O

Within O
the O
composite O
mask O
, O
statistical O
maps O
were O
thresholded O
correcting O
for O
family-wise O
error O
at O
Pcorrected O
< O
0.05 O
( O
Pvoxel-wise O
< O
0.001 O
, O
cluster O
extent O
: O
9 O
voxels O
, O
7684 O
voxels O
in O
composite O
mask O
) O
. O

For O
graphical O
examination O
and O
follow-up O
analyses O
, O
we O
extracted O
the O
mean O
contrast O
values O
( O
iE O
− O
iC O
βs O
) O
as O
well O
as O
the O
individual O
β O
coefficients O
for O
iE O
and O
iC O
trials O
from O
those O
ROIs O
showing O
smoker O
versus O
nonsmoker O
differences O
. O

To O
link O
altered O
brain O
activity O
among O
smokers O
with O
a O
clinically O
relevant O
construct O
, O
we O
conducted O
a O
priori O
hypothesized O
Pearson O
’ O
s O
correlations O
between O
the O
[ O
iE O
− O
iC O
] O
contrast O
values O
from O
identified O
ROIs O
and O
smokers O
’ O
FTND O
scores O
that O
reflect O
trait O
levels O
of O
addiction O
severity O
. O

The O
P O
values O
resulting O
from O
these O
a O
priori O
correlation O
analyses O
were O
Bonferronni-corrected O
( O
n O
= O
3 O
; O
the O
number O
of O
ROIs O
considered O
) O
. O

To O
further O
link O
feedback-related O
brain O
activity O
from O
all O
participants O
with O
self-reported O
affect O
, O
we O
conducted O
post O
hoc O
exploratory O
correlations O
between O
[ O
iE O
− O
iC O
] O
contrast O
values O
and O
each O
participant O
’ O
s O
PANAS O
scores O
. O

Given O
that O
we O
were O
interested O
in O
trait O
levels O
of O
affect O
( O
paralleling O
the O
session-averaged O
, O
trait-level O
assessment O
of O
brain O
activity O
) O
, O
we O
computed O
a O
session-averaged O
metric O
of O
positive O
and O
negative O
affect O
. O

Specifically O
, O
participants O
completed O
the O
PANAS O
at O
each O
study O
visit O
, O
and O
we O
were O
interested O
in O
an O
individual O
’ O
s O
general O
level O
of O
affect O
as O
opposed O
to O
session-to-session O
fluctuations O
. O

These O
exploratory O
correlation O
analyses O
were O
not O
Bonferronni-corrected O
for O
multiple O
comparisons O
. O

Drug O
effects O
To O
delineate O
functional O
alterations O
linked O
with O
acute O
drug O
administration O
, O
we O
assessed O
β O
coefficient O
images O
from O
iC O
( O
positive O
) O
feedback O
trials O
in O
a O
LME O
framework O
( O
3dLME O
, O
v1.9.8 O
) O
, O
including O
factors O
for O
GROUP O
( O
between O
participants O
: O
smoker O
versus O
nonsmoker O
) O
, O
PATCH O
( O
within O
participants O
: O
nicotine O
versus O
placebo O
) O
, O
and O
PILL O
( O
within O
participants O
: O
pre-pill O
, O
varenicline O
, O
versus O
placebo O
) O
. O

The O
LME O
framework O
was O
used O
given O
missing O
session O
data O
associated O
with O
our O
motion O
censoring O
criteria O
described O
above O
. O

We O
focused O
on O
iC O
feedback O
trials O
given O
that O
a O
larger O
effect O
size O
was O
observed O
for O
these O
trials O
( O
relative O
to O
iE O
feedback O
) O
when O
assessing O
smoker O
versus O
nonsmoker O
differences O
in O
the O
group O
effects O
analysis O
above O
. O

Significant O
interaction O
effects O
involving O
the O
GROUP O
factor O
and/or O
PATCH O
main O
effects O
were O
followed O
by O
within-group O
( O
i.e. O
, O
smokers O
) O
LME O
analyses O
including O
PATCH O
and O
PILL O
as O
factors O
. O

Main O
and O
interaction O
effects O
were O
of O
interest O
. O

Within O
this O
analysis O
model O
, O
a O
general O
linear O
t O
test O
was O
performed O
comparing O
nicotine O
versus O
placebo O
patch O
to O
visually O
represent O
the O
direction O
of O
drug-related O
alterations O
( O
i.e. O
, O
nicotine O
< O
placebo O
, O
nicotine O
> O
placebo O
) O
associated O
with O
the O
PATCH O
main O
effect O
. O

To O
maximize O
the O
potential O
for O
producing O
generalizable O
results O
and O
minimizing O
type O
I O
error O
rates O
, O
this O
LME O
model O
used O
a O
“ O
maximal O
random O
effects O
structure O
” O
( O
i.e. O
, O
included O
random O
intercepts O
for O
participants O
and O
random O
slopes O
for O
the O
PATCH O
, O
PILL O
, O
and O
PATCH O
* O
PILL O
effects O
; O
-ranEff O
‘ O
~1 O
+ O
patch O
+ O
pill O
+ O
pill O
* O
patch O
’ O
) O
. O

Statistical O
maps O
were O
thresholded O
correcting O
for O
family-wise O
error O
within O
the O
composite O
mask O
as O
described O
above O
for O
the O
group O
effects O
analysis O
. O

We O
extracted O
the O
β O
coefficients O
from O
both O
the O
iC O
and O
iE O
trials O
from O
those O
ROIs O
separately O
showing O
drug-induced O
effects O
for O
all O
six O
drug O
conditions O
and O
across O
both O
groups O
( O
smokers O
and O
nonsmokers O
) O
for O
qualitative O
graphical O
[ O
to O
avoid O
a O
circular O
analysis O
] O
and/or O
selective O
quantitative O
statistical O
examination O
, O
thereby O
facilitating O
comprehensive O
interpretation O
of O
pharmacological O
effects O
. O

While O
a O
selective O
analysis O
of O
smokers O
’ O
iC O
β O
coefficients O
would O
constituent O
a O
circular O
analysis O
, O
we O
extracted O
these O
parameter O
estimates O
only O
for O
graphical O
representation O
. O

Given O
that O
the O
iE O
β O
coefficients O
were O
unrelated O
to O
the O
statistical O
test O
used O
to O
identify O
voxels O
of O
interest O
, O
we O
assessed O
parameter O
estimates O
from O
select O
regions O
in O
a O
GROUP O
* O
PATCH O
* O
PILL O
mixed-effects O
ANOVA O
using O
SPSS O
. O

Significant O
interactions O
involving O
the O
GROUP O
factor O
and/or O
PATCH O
main O
effects O
were O
followed O
by O
within-group O
, O
repeated-measures O
ANOVAs O
including O
PATCH O
and O
PILL O
as O
factors O
. O

To O
link O
session-to-session O
fluctuations O
in O
brain O
activity O
among O
smokers O
with O
a O
clinically O
relevant O
construct O
, O
we O
conducted O
a O
priori O
hypothesized O
RMcorr O
between O
session-specific O
iC O
β O
values O
from O
identified O
ROIs O
and O
smokers O
’ O
session-specific O
TCQ O
scores O
that O
reflect O
a O
state-level O
measure O
of O
withdrawal O
status O
. O

RMcorr O
is O
a O
statistical O
procedure O
implemented O
in O
R O
( O
v3.5.0 O
) O
to O
characterize O
the O
within-participant O
association O
between O
two O
measures O
assessed O
on O
two O
or O
more O
occasions O
common O
across O
all O
participants O
. O

The O
P O
values O
resulting O
from O
these O
a O
priori O
RMcorr O
analyses O
were O
Bonferronni-corrected O
( O
n O
= O
3 O
; O
the O
number O
of O
ROIs O
considered O
) O
. O

To O
further O
link O
session-to-session O
fluctuations O
in O
brain O
activity O
from O
all O
participants O
with O
self-reported O
anhedonia O
, O
we O
conducted O
post O
hoc O
exploratory O
RMcorr O
between O
session-specific O
iC O
beta O
values O
and O
each O
participant O
’ O
s O
session-specific O
RSAS O
scores O
. O

These O
exploratory O
RMcorr O
analyses O
were O
not O
corrected O
for O
multiple O
comparisons O
. O

